Insider Transactions in Q1 2023 at Johnson & Johnson (JNJ)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 06
2023
|
James D. Swanson EVP, CIO |
SELL
Open market or private sale
|
Direct |
1,061
-10.33%
|
$163,394
$154.66 P/Share
|
|
Feb 13
2023
|
Elizabeth Forminard Executive VP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
924
-14.42%
|
$149,688
$162.01 P/Share
|
|
Feb 13
2023
|
Elizabeth Forminard Executive VP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
2,555
+28.51%
|
-
|
|
Feb 13
2023
|
Robert J Decker VP Corporate Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
397
-2.29%
|
$64,314
$162.01 P/Share
|
|
Feb 13
2023
|
Robert J Decker VP Corporate Controller |
BUY
Grant, award, or other acquisition
|
Direct |
1,451
+7.73%
|
-
|
|
Feb 13
2023
|
Joaquin Duato CEO and Chairman of the Board |
SELL
Payment of exercise price or tax liability
|
Direct |
13,599
-4.12%
|
$2,203,038
$162.01 P/Share
|
|
Feb 13
2023
|
Joaquin Duato CEO and Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
31,319
+8.67%
|
-
|
|
Feb 13
2023
|
Peter Fasolo Exec VP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,765
-4.49%
|
$933,930
$162.01 P/Share
|
|
Feb 13
2023
|
Peter Fasolo Exec VP, Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,468
+8.85%
|
-
|
|
Feb 13
2023
|
William Hait EVP, Chief EI and Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,586
-4.97%
|
$742,932
$162.01 P/Share
|
|
Feb 13
2023
|
William Hait EVP, Chief EI and Med Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,640
+9.45%
|
-
|
|
Feb 13
2023
|
Ashley Mc Evoy EVP, WW Chair, MedTech |
SELL
Payment of exercise price or tax liability
|
Direct |
7,158
-11.55%
|
$1,159,596
$162.01 P/Share
|
|
Feb 13
2023
|
Ashley Mc Evoy EVP, WW Chair, MedTech |
BUY
Grant, award, or other acquisition
|
Direct |
17,994
+22.5%
|
-
|
|
Feb 13
2023
|
Thibaut Mongon Exec VP, WW Chair, Cons Health |
SELL
Payment of exercise price or tax liability
|
Direct |
6,430
-8.89%
|
$1,041,660
$162.01 P/Share
|
|
Feb 13
2023
|
Thibaut Mongon Exec VP, WW Chair, Cons Health |
BUY
Grant, award, or other acquisition
|
Direct |
13,710
+15.93%
|
-
|
|
Feb 13
2023
|
James D. Swanson EVP, CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
918
-8.2%
|
$148,716
$162.01 P/Share
|
|
Feb 13
2023
|
James D. Swanson EVP, CIO |
BUY
Grant, award, or other acquisition
|
Direct |
3,228
+22.38%
|
-
|
|
Feb 13
2023
|
Jennifer L Taubert EVP, WWC. Innovative Medicine |
SELL
Payment of exercise price or tax liability
|
Direct |
10,569
-7.04%
|
$1,712,178
$162.01 P/Share
|
|
Feb 13
2023
|
Jennifer L Taubert EVP, WWC. Innovative Medicine |
BUY
Grant, award, or other acquisition
|
Direct |
21,422
+12.49%
|
-
|
|
Feb 13
2023
|
Kathryn E Wengel EVP, Chief TO and Risk Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,891
-5.87%
|
$792,342
$162.01 P/Share
|
|
Feb 13
2023
|
Kathryn E Wengel EVP, Chief TO and Risk Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,839
+11.52%
|
-
|
|
Feb 13
2023
|
Joseph J Wolk Exec VP, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,578
-14.55%
|
$1,389,636
$162.01 P/Share
|
|
Feb 13
2023
|
Joseph J Wolk Exec VP, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
20,693
+25.97%
|
-
|
|
Feb 13
2023
|
Vanessa Broadhurst EVP, Global Corp Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
1,440
-6.98%
|
$233,280
$162.01 P/Share
|
|
Feb 13
2023
|
Vanessa Broadhurst EVP, Global Corp Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
3,981
+16.17%
|
-
|
|
Feb 10
2023
|
Elizabeth Forminard Executive VP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
380
-8.98%
|
$61,560
$162.08 P/Share
|
|
Feb 10
2023
|
Elizabeth Forminard Executive VP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
1,022
+19.45%
|
-
|
|
Feb 10
2023
|
Peter Fasolo Exec VP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
761
-0.65%
|
$123,282
$162.08 P/Share
|
|
Feb 10
2023
|
Peter Fasolo Exec VP, Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,078
+1.75%
|
-
|
|
Feb 10
2023
|
Thibaut Mongon Exec VP, WW Chair, Cons Health |
SELL
Payment of exercise price or tax liability
|
Direct |
826
-1.39%
|
$133,812
$162.08 P/Share
|
|
Feb 10
2023
|
Thibaut Mongon Exec VP, WW Chair, Cons Health |
BUY
Exercise of conversion of derivative security
|
Direct |
2,285
+3.7%
|
-
|
|
Feb 10
2023
|
William Hait EVP, Chief EI and Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,399
-1.66%
|
$226,638
$162.08 P/Share
|
|
Feb 10
2023
|
William Hait EVP, Chief EI and Med Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,856
+4.38%
|
-
|
|
Feb 10
2023
|
Ashley Mc Evoy EVP, WW Chair, MedTech |
SELL
Payment of exercise price or tax liability
|
Direct |
823
-1.84%
|
$133,326
$162.08 P/Share
|
|
Feb 10
2023
|
Ashley Mc Evoy EVP, WW Chair, MedTech |
BUY
Exercise of conversion of derivative security
|
Direct |
2,999
+6.27%
|
-
|
|
Feb 10
2023
|
Jennifer L Taubert EVP, WWC. Innovative Medicine |
SELL
Payment of exercise price or tax liability
|
Direct |
1,289
-0.99%
|
$208,818
$162.08 P/Share
|
|
Feb 10
2023
|
Jennifer L Taubert EVP, WWC. Innovative Medicine |
BUY
Exercise of conversion of derivative security
|
Direct |
3,570
+2.67%
|
-
|
|
Feb 10
2023
|
Joseph J Wolk Exec VP, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
979
-2.49%
|
$158,598
$162.08 P/Share
|
|
Feb 10
2023
|
Joseph J Wolk Exec VP, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,449
+8.08%
|
-
|
|
Feb 10
2023
|
Kathryn E Wengel EVP, Chief TO and Risk Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
667
-0.91%
|
$108,054
$162.08 P/Share
|
|
Feb 10
2023
|
Kathryn E Wengel EVP, Chief TO and Risk Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,807
+2.41%
|
-
|
|
Feb 10
2023
|
Joaquin Duato CEO and Chairman of the Board |
SELL
Payment of exercise price or tax liability
|
Direct |
2,267
-0.75%
|
$367,254
$162.08 P/Share
|
|
Feb 10
2023
|
Joaquin Duato CEO and Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
5,220
+1.71%
|
-
|
|
Feb 10
2023
|
James D. Swanson EVP, CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
388
-4.64%
|
$62,856
$162.08 P/Share
|
|
Feb 10
2023
|
James D. Swanson EVP, CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,291
+13.38%
|
-
|
|
Feb 10
2023
|
Vanessa Broadhurst EVP, Global Corp Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
597
-3.46%
|
$96,714
$162.08 P/Share
|
|
Feb 10
2023
|
Vanessa Broadhurst EVP, Global Corp Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
1,592
+8.45%
|
-
|
|
Feb 10
2023
|
Robert J Decker VP Corporate Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
191
-1.19%
|
$30,942
$162.08 P/Share
|
|
Feb 10
2023
|
Robert J Decker VP Corporate Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
581
+3.49%
|
-
|
|
Jan 17
2023
|
Joaquin Duato CEO and Chairman of the Board |
SELL
Payment of exercise price or tax liability
|
Direct |
98,795
-25.04%
|
$17,091,535
$173.43 P/Share
|